Tech Company Inital Public Offerings

Stemline Therapeutics IPO

Stemline Therapeutics, based in New York, went public on 1/29/2013.

Transaction Overview

Announced On
1/29/2013
Transaction Type
IPO
Amount
$33,000,000
Proceeds Purpose
Proceeds purposes are on file with company statements at the SEC.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
750 Lexington Ave. 11th Floor
New York, NY 10022
USA
Email Address
Overview
Stemline Therapeutics, Inc. (NASDAQ: STML) is a clinical stage biotechnology company developing oncology compounds directed to cancer stem cell targets. Stemline's lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia and leukemia cancer stem cells.
Profile
Stemline Therapeutics LinkedIn Company Profile
Social Media
Stemline Therapeutics Company Twitter Account
Company News
Stemline Therapeutics News
Facebook
Stemline Therapeutics on Facebook
YouTube
Stemline Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Ivan Bergstein
  Ivan Bergstein LinkedIn Profile  Ivan Bergstein Twitter Account  Ivan Bergstein News  Ivan Bergstein on Facebook
Chief Operating Officer
Kenneth Hoberman
  Kenneth Hoberman LinkedIn Profile  Kenneth Hoberman Twitter Account  Kenneth Hoberman News  Kenneth Hoberman on Facebook
VP - Finance
David Gionco
  David Gionco LinkedIn Profile  David Gionco Twitter Account  David Gionco News  David Gionco on Facebook


 

 

Browse more venture capital transactions:

Prev: 1/29/2013: Practically Green venture capital transaction
Next: 1/29/2013: WatchDox venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to record tech company VC transactions. VC investment data records on this site are derived from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary